Cargando…
Major depressive symptoms in breast cancer patients with ovarian function suppression: a cross-sectional study comparing ovarian ablation and gonadotropin-releasing hormone agonists
BACKGROUND: Ovarian function suppression (OFS) is indicated in premenopausal women with early or metastasis breast cancer, which may be achieved with similar effect by gonadotropin-releasing hormone agonists (GnRHa) or ovarian ablation (OA). We examined whether there were differences in major depres...
Autores principales: | Jiang, Junhan, Xu, Junnan, Cai, Li, Man, Li, Niu, Limin, Hu, Juan, Sun, Tao, Zheng, Xinyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666024/ https://www.ncbi.nlm.nih.gov/pubmed/34895183 http://dx.doi.org/10.1186/s12888-021-03611-6 |
Ejemplares similares
-
Effect of Timing of Gonadotropin-Releasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer
por: Shin, Jae Jun, et al.
Publicado: (2020) -
Functional Ovarian Cysts in Artificial Frozen-Thawed Embryo Transfer Cycles With Depot Gonadotropin-Releasing Hormone Agonist
por: Ji, Hui, et al.
Publicado: (2022) -
Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve
por: Lin, Ming-Huei, et al.
Publicado: (2019) -
Adrenocorticotropic Hormone Suppresses Gonadotropin-Stimulated Estradiol Release from Zebrafish Ovarian Follicles
por: Alsop, Derek, et al.
Publicado: (2009) -
Gonadotropin-releasing hormone agonist protects ovarian function in young patients with ovarian malignancy undergoing platinum-based chemotherapy: A prospective study
por: Xie, Ya, et al.
Publicado: (2022)